Table 2. Odds Ratios for the Association Between Race and Ethnicity and Therapeutic Inertia in the Systolic Blood Pressure Intervention Trial by Randomized Treatment Arm.

Variable	% (95% CI)
	Non-Hispanic White	Non-Hispanic Black	Hispanic
Standard arm
Unique participants, No.	2451	1306	384
Participant-visits, No.	13 726	7372	1746
Prevalence
Overalla	59.8 (58.9-60.7)	56.8 (54.4-59.2)	59.7 (56.5-63.0)
12 Mob	55.7 (51.3-60.1)	54.3 (48.0-60.4)	64.3 (51.2-75.5)
36 Mob	61.9 (55.3-68.1)	54.0 (44.8-62.9)	84.6 (70.3-92.8)
Adjusted odds ratio (N = 4092)b,c,d	1 [Reference]	0.85 (0.79-0.92)	1.00 (0.90-1.13)
Intensive arm
Unique participants, No.	2639	1329	447
Participant-visits, No.	22 319	10 716	2418
Prevalence
Overalla	56.0 (55.2-56.7)	54.5 (52.4-56.6)	51.0 (47.4-54.5)
12 Mob	54.8 (51.0-58.6)	51.4 (45.7-57.0)	35.5 (25.7-46.7)
36 Mob	67.0 (62.0-71.7)	66.7 (58.9-73.6)	50.0 (33.6-66.4)
Adjusted odds ratio (N = 4377)b,c,d	1 [Reference]	0.94 (0.88-1.01)	0.89 (0.79-1.00)

^a This is the estimated overall prevalence of therapeutic inertia among included participant-visits across time (1 to 48 months) accounting for within-patient correlation.

^b This is the observed prevalence of therapeutic inertia among visits at 12 or 36 months.

^c Sample sizes for individual models represent total unique participants in the model.

^d Results are shown for Model 3 which is adjusted for race/ethnicity, time, age, sex, education, employment, living with others, insurance status, source of care, smoking status, body mass index, depression, statin use, aspirin use, as well as systolic blood pressure, eGFR, serum potassium, serum sodium, number of antihypertensive medications, prior mTIS, ACEI/ARB, CCB, thiazide diuretic, loop diuretic, beta-blocker, alpha-blocker, number of non-antihypertensive medications, plus adjustment for serious adverse events reported within 1 month prior of the study visit.